FCGR3A and neoplasm: In this setting, GD2-CAR-engineered lymphocytes may be of particular benefit, since they link antibody-mediated recognition of tumor cells directly with potent intracellular signaling in genetically modified effector lymphocytes, bypassing variable activity of endogenous immune cells and the potential influence of CD16 polymorphisms on antitumor activity [43].